Promise and challenge of systemic sclerosis therapies

Yumeko Kawano¹, Lorinda Chung^{2

3}

Affiliations

¹ Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA.
² Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA. shauwei@stanford.edu.
³ VA Palo Alto Health Care System, Palo Alto, CA, USA. shauwei@stanford.edu.

Comment

Yumeko Kawano et al. Nat Rev Rheumatol. 2021 Oct.

. 2021 Oct;17(10):581-582.

doi: 10.1038/s41584-021-00678-z.

Yumeko Kawano¹, Lorinda Chung^{2

3}

¹ Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA.
² Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA. shauwei@stanford.edu.
³ VA Palo Alto Health Care System, Palo Alto, CA, USA. shauwei@stanford.edu.

No abstract available

Comment on

An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.
Campochiaro C, Allanore Y. Campochiaro C, et al. Arthritis Res Ther. 2021 Jun 1;23(1):155. doi: 10.1186/s13075-021-02536-5. Arthritis Res Ther. 2021. PMID: 34074331 Free PMC article.

1. Hao, Y. et al. Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheum. 69, 1067–1077 (2017). - DOI
1. Campochiaro, C. & Allanore, Y. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years. Arthritis Res. Ther. 23, 155 (2021). - DOI
1. Chung, M. P. & Chung, L. Drugs in phase I and phase II clinical trials for systemic sclerosis. Expert Opin. Investig. Drugs. 29, 349–362 (2020). - DOI
1. Distler, O. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 380, 2518–2528 (2019). - DOI
1. Khanna, D. et al. Tocilizumab in systemic sclerosis: a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 8, 963–974 (2020). - DOI